Want to see GB:OBI full AI Analyst Report?
OBI Stock Chart & Stats
8.75 p
-0.23 p(-2.61%)
At close: 4:00 PM EST
8.75 p
-0.23 p(-2.61%)
Day’s Range― - ―
52-Week Range7.50 p - 18.50 p
Previous CloseN/A
Volume7.12K
Average Volume (3M)160.07K
Market Cap
£72.57M
Enterprise Value109.78M
Total Cash (Recent Filing)£10.58M
Total Debt (Recent Filing)£413.50K
Price to Earnings (P/E)―
Beta0.18
Next Earnings
Sep 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding518,366,940
10 Day Avg. Volume119,918
30 Day Avg. Volume160,072
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)21.53
Price to Sales (P/S)28.32
P/FCF Ratio-3.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)£12.20M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained ~18% revenue growth in 2025 indicates improving commercial traction and product adoption in core markets. Over 2-6 months this supports scalable revenue base potential, increasing odds of absorbing fixed costs and funding further clinical/commercial rollout if growth persists.
Low LeverageVery low debt relative to equity (debt-to-equity ~0.12) provides balance-sheet flexibility and lowers near-term refinancing pressure. This structural conservatism gives management optionality to access capital or prioritize R&D without immediate loan covenants constraining strategy.
Focused Clinical NicheA targeted product strategy in antimicrobial photodisinfection addresses durable healthcare needs—hospital-acquired infection prevention. Structural demand for infection-control solutions and clear clinical use cases supports steady market relevance and potential long-term adoption pathways.
Bears Say
Severe Cash BurnLarge and worsening negative operating cash flow (~-£23.9M in 2025) signals ongoing high cash burn that materially increases financing risk. Over a multi-month horizon this forces reliance on capital markets or dilution unless costs are cut or revenue scales rapidly, constraining strategic choices.
Margin DeteriorationA sharp drop in gross margin from ~64% to ~41% coupled with a deeply negative net margin (~-1,116%) undermines the durability of revenue gains. Structural margin pressure suggests pricing, cost, or mix issues that must be remedied to translate top-line growth into sustainable profitability.
Funding DependenceHistorical negative equity and sharp equity swings point to recurring reliance on external funding and dilution risk. This pattern weakens long-term financial predictability and may limit hiring, partnerships, or investment choices absent clear path to cash-flow break-even.
Ondine Biomedical, Inc. News
OBI FAQ
What was Ondine Biomedical, Inc.’s price range in the past 12 months?
Ondine Biomedical, Inc. lowest share price was 7.50 p and its highest was 18.50 p in the past 12 months.
What is Ondine Biomedical, Inc.’s market cap?
Ondine Biomedical, Inc.’s market cap is £72.57M.
When is Ondine Biomedical, Inc.’s upcoming earnings report date?
Ondine Biomedical, Inc.’s upcoming earnings report date is Sep 30, 2026 which is in 70 days.
How were Ondine Biomedical, Inc.’s earnings last quarter?
Ondine Biomedical, Inc. released its earnings results on Jun 04, 2026. The company reported -0.019 p earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Ondine Biomedical, Inc. overvalued?
According to Wall Street analysts Ondine Biomedical, Inc.’s price is currently Overvalued.
Does Ondine Biomedical, Inc. pay dividends?
Ondine Biomedical, Inc. does not currently pay dividends.
What is Ondine Biomedical, Inc.’s EPS estimate?
Ondine Biomedical, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ondine Biomedical, Inc. have?
Ondine Biomedical, Inc. has 518,366,940 shares outstanding.
What happened to Ondine Biomedical, Inc.’s price movement after its last earnings report?
Ondine Biomedical, Inc. reported an EPS of -0.019 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.448%.
Which hedge fund is a major shareholder of Ondine Biomedical, Inc.?
Currently, no hedge funds are holding shares in GB:OBI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ondine Biomedical, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
40.62%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.57%
Trailing 12-Months
Company Description
Ondine Biomedical, Inc.
Ondine Biomedical Inc., a life sciences firm, specializes in the research, development, and commercialization of advanced antimicrobial photodisinfection therapies, operating both within Canada and internationally. Its foundational technology is Photodisinfection, a state-of-the-art, light-based topical antimicrobial approach designed to neutralize detrimental pathogens. The company's flagship product, Steriwave, is a medical device leveraging photodisinfection to eradicate harmful nasal pathogens, thereby significantly mitigating healthcare-acquired infections. Furthermore, Ondine Biomedical's development pipeline includes a topical antiviral treatment for the upper respiratory tract aimed at reducing SARS-CoV-2 viral load and transmission; a solution for addressing chronic rhinosinusitis; OND1002, an agent for disinfecting endotracheal tubes to decrease the occurrence of ventilator-associated pneumonia; and OND1003, formulated for the decolonization of burns and wounds. Established in 1996, the company maintains its corporate headquarters in Vancouver, Canada.
Technical Analysis
Avacta Group plc
―
SkinBioTherapeutics
―
4basebio UK Societas
―
Poolbeg Pharma Ltd.
―
Oxford Nanopore Technologies PLC
―